Clinical Trials Logo

Clinical Trial Summary

Guillain-Barre syndrome is an immune-mediated acute inflammatory peripheral neuropathy. The currently effective treatment methods include intravenous immunoglobulin and plasma exchange. Immunoadsorption has been widely used to treat immune-related diseases. There are currently no prospective large-sample clinical trials of immunoadsorption therapy for Guillain-Barre syndrome. The neuro-intensive care unit of the First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, randomized parallel controlled clinical study on the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin (IVIG) in the treatment of Guillain-Barre syndrome. It is estimated that 204 patients with Guillain-Barre syndrome will be included. The patients will be randomly assigned to the immunoadsorption group and the IVIG group. The primary outcome measure: changes in Hughes scores (4 weeks after starting treatment vs. baseline (before starting treatment) ). This study aims to explore the efficacy and safety of protein A immunoadsorption and intravenous immunoglobulin in the treatment of Guillain-Barre syndrome.


Clinical Trial Description

Guillain-Barre syndrome (GBS) is an immune-mediated acute inflammatory peripheral neuropathy. The currently proven effective treatment methods include intravenous immunoglobulin and plasma exchange. In the clinical treatment process, the plasma source is often stressed, forcing the treatment to be terminated. Intravenous immunoglobulin therapy may cause allergies. Based on the above reasons, immunosorbent technology came into being. Immunoadsorption technology is widely used in clinical treatment of immune-related diseases. Protein A can recognize and bind to the Fc segment of human antibodies. The protein A immunosorbent column uses recombinant staphylococcal protein A as its ligand. The protein can specifically recognize and bind to the Fc segment of human antibodies, so it can adsorb human antibodies, mainly immunoglobulin G, and can adsorb immunoglobulin M and immunoglobulin A at the same time. The binding of protein A and antibody is reversible. Immunoadsorption therapy has obvious advantages: The patient's own plasma is transfused without replacement fluid; It can prevent infection Diseases such as viral hepatitis, AIDS, etc.; The adsorption is selective or specific, and normal plasma components including coagulation factors, etc., only slightly decrease; Does not affect the simultaneous drug treatment; The protein A immunosorbent column can be reused; The treatment effect is better, and the amount of plasma purified by a single immunoadsorption is 1.5 to 3 times that of plasma exchange. The First Affiliated Hospital of Zhengzhou University is preparing to carry out a prospective, multi-center, randomized parallel controlled clinical study on the effectiveness and safety of protein A immunoadsorption and intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. The control group received intravenous immunoglobulin injections using the standard treatment recommended by the Guilan-Barre Syndrome Guidelines. Compare the effectiveness and safety of the two treatment regimens in the treatment of Guillain-Barre syndrome, and explore a more effective and safe treatment regimen for the treatment of Guillain-Barre syndrome. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05114941
Study type Interventional
Source The First Affiliated Hospital of Zhengzhou University
Contact Wang Miao, Prof
Phone 0086-13592567185
Email [email protected]
Status Not yet recruiting
Phase N/A
Start date December 1, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04053452 - Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome N/A
Recruiting NCT02582853 - sCD163 as a Potential Biomarker in Guillain- Barré Syndrome N/A
Completed NCT00056810 - Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Phase 2
Recruiting NCT05104762 - IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients Phase 2/Phase 3
Recruiting NCT03801135 - Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation N/A
Active, not recruiting NCT01655394 - Change of Nerve Conduction Properties in IVIg Dependent Neuropathies N/A
Recruiting NCT04927598 - Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Not yet recruiting NCT04092140 - Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
Not yet recruiting NCT04550611 - Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome N/A
Not yet recruiting NCT04674163 - Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases. N/A
Withdrawn NCT03268304 - Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
Withdrawn NCT02459808 - Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome N/A
Not yet recruiting NCT04752566 - A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Phase 3
Completed NCT00575653 - Safety Study of GBS Following Menactra Meningococcal Vaccination N/A
Terminated NCT00004833 - Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome N/A
Completed NCT01005524 - Brain Computer Interface for Communication in ICU: a Feasibility Study N/A
Recruiting NCT04249752 - Biomarkers in Polyradiculoneuropathies
Completed NCT03206541 - Neurologic Manifestations of the Arbovirus Infection in Colombia
Completed NCT03941184 - Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
Active, not recruiting NCT03826056 - Neurology Inpatient Clinical Education Trial N/A